Welcome to our dedicated page for BGCP news (Ticker: BGCP), a resource for investors and traders seeking the latest updates and insights on BGCP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BGCP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BGCP's position in the market.
BGC Partners announced the pricing of $300 million in 4.375% senior notes, set to mature on December 15, 2025. The notes will provide semi-annual interest payments beginning December 15, 2020. Proceeds will be used to repurchase existing 5.125% senior notes due 2021 and for general corporate purposes. The offering is private and exempt from the registration requirements of the Securities Act. Forward-looking statements regarding the impact of COVID-19 on BGC's business are included, highlighting potential risks and uncertainties.